Bevacizumab (Avastin) is a humanized anti-VEGF monoclonal antibody, which is applied for the treatment of patients with metastatic colorectal cancer (18), non-small cell lung cancer (NSCLC) (19), ovarian cancer and other types of cancer (20,21). The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.